The underlying motivation for this research stems from the clinical challenge posed by the risk of cancer recurrence following radical prostatectomy. Despite surgical removal of the prostate gland, a subset of patients remains vulnerable to disease relapse, often manifested by biochemical recurrence signaled through rising prostate-specific antigen (PSA) levels. Conventional radiation therapy, administered over multiple weeks, has been the mainstay for mitigating this risk, but its duration and toxicity can substantially impact patient quality of life. Therefore, the emergence of SBRT as a streamlined alternative holds promise but necessitates rigorous validation given the anatomical complexity of post-surgical pelvic tissues.

Within this pioneering phase 2 clinical trial, dubbed SCIMITAR, a cohort of 100 patients identified as high risk for recurrence after radical prostatectomy participated at both UCLA and the University of Southern California. These patients underwent SBRT delivered in an intensive course of five sessions spread over approximately 10 days. Additionally, treatment protocols were individualized, incorporating hormone therapy and lymph node irradiation in certain cases based on clinical indications. Crucially, patients were followed longitudinally for an average of 4.5 years to meticulously evaluate oncological outcomes, adverse effects, and health-related quality of life metrics.

The trial’s findings delineate a compelling narrative that SBRT is not only a safe therapeutic modality in the postoperative setting but also exhibits oncological efficacy on par with conventional fractionation schemes. Specifically, a remarkable 60% of participants achieved sustained freedom from biochemical recurrence, evidenced by stable PSA levels and an absence of disease signs culminating in the omission of further hormone therapy. This outcome underpins the potential of SBRT to deliver durable cancer control despite its condensed treatment timeframe.

Moreover, the study delineates a nuanced advantage of SBRT in reducing recurrence risk, particularly in patients who did not receive adjunct hormone therapy. The data suggest that SBRT may offer superior prophylactic benefits compared to traditional radiation courses, a finding that could recalibrate clinical decision-making processes and favor more expedient radiation strategies. This aspect underscores the evolving landscape of precision radiation oncology where treatment intensity and duration are finely balanced against therapeutic gains and toxicity profiles.

Adverse event monitoring revealed that side effects attributable to SBRT were predominantly manageable and in alignment with expectations from conventional radiation. The incidence of severe bowel toxicity was reported to be relatively low, affecting only 7% of participants, a reassuring statistic given the proximity of intestinal structures to the radiation field. Urinary complications were more frequent, observed in roughly one-third of patients, yet these too were largely mitigated by the incorporation of MRI-guided radiation therapy techniques. This innovation enhances treatment precision by enabling real-time visualization of the target and surrounding organs, thereby minimizing inadvertent radiation exposure to sensitive tissues.

A pivotal aspect of the study was the comprehensive assessment of patient-reported quality of life outcomes across urinary, bowel, and sexual health domains. Despite the high radiation doses administered in a truncated timeframe, most patients reported maintenance of baseline functional status with minimal deleterious effects. This finding is particularly salient as it highlights the balance between treatment intensity and preservation of life quality, a critical consideration in cancer survivorship care models.

The research contextualizes these insights within the continuum of prior investigations that explored SBRT’s feasibility after prostatectomy, consolidating evidence over a median follow-up exceeding four years. Such longitudinal data are invaluable as they affirm the durability and reproducibility of benefits observed in earlier reports limited to shorter follow-up periods. Collectively, these advancements herald a potential paradigm shift towards shorter, patient-friendly radiation regimens that do not compromise clinical outcomes.

Dr. Amar Kishan, serving as co-first author and a luminary in radiation oncology, emphasized that these findings hold transformative potential. He elucidated that the accelerated treatment delivery not only simplifies the therapeutic process for patients but also aligns with modern oncologic imperatives aiming for personalized, less intrusive interventions. The meticulous management of side effects, particularly with MRI guidance, further accentuates the technological progress enabling safer radiation delivery in anatomically complex postoperative beds.

Published in the eminent journal European Urology and highlighted at the 2025 American Society for Radiation Oncology Annual Meeting, this study represents a landmark in prostate cancer treatment innovation. It draws attention to the evolving role of advanced radiation modalities harnessing precision imaging and sophisticated dosing algorithms to optimize patient outcomes. The collaboration of multidisciplinary teams and robust funding from federal agencies like the NIH and the Department of Defense reflects the critical societal investment in advancing cancer therapeutics.

Looking ahead, these emergent data lay a foundation for expanding SBRT indications and refining patient selection criteria to maximize individualized benefits. Future investigations may integrate molecular and imaging biomarkers to tailor radiation doses further and synergize with systemic therapies. Such integrated oncologic strategies could herald an era of curative-intent treatment approaches with minimal toxicity and maximal patient convenience.

In summary, the UCLA-led research provides compelling evidence that stereotactic body radiotherapy, delivered in an expedited five-session format, stands as a safe, effective, and patient-centric alternative to protracted radiation courses after prostatectomy. This advancement promises to alleviate treatment burdens, reduce healthcare costs, and maintain high standards of cancer control and quality of life, potentially redefining postoperative management for men with prostate cancer worldwide.

Subject of Research: Stereotactic body radiotherapy (SBRT) for prostate cancer recurrence prevention after radical prostatectomy

Article Title: — (Not specified in the provided content)

News Publication Date: — (Not specified in the provided content)

Web References:

• UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
• Study published in European Urology: https://www.sciencedirect.com/science/article/pii/S0302283825046998?dgcid=author
• Earlier findings press release: https://www.uclahealth.org/news/release/shorter-radiation-therapy-after-prostate-surgery-safe-study

References:

• Published article DOI: 10.1016/j.eururo.2025.09.4149

Keywords:
Prostate cancer, cancer recurrence, radiation therapy, stereotactic body radiotherapy, SBRT, MRI-guided radiation, bladder toxicity, bowel toxicity, quality of life, postoperative treatment, cancer therapeutics, radiation oncology

The Steven A. Leibel Memorial Award, jointly presented by the American Society for Radiation Oncology (ASTRO) and the American Board of Radiology (ABR) Foundation, acknowledges the innovative contributions and leadership that early-career clinicians bring to radiation oncology. Dr. Kishan’s selection reflects his commitment to integrating advanced radiation techniques with translational and clinical research to improve patient outcomes substantially. This national honor not only celebrates his research accomplishments but also highlights his dedication to transforming cancer treatment by refining and individualizing radiotherapeutic strategies.

At UCLA, Dr. Kishan has established a robust clinical and translational research agenda spanning over eight years, focusing extensively on genitourinary oncology. As chief of the genitourinary oncology service, he is internationally renowned for his expertise in stereotactic body radiotherapy (SBRT) and MRI-guided radiation therapy. SBRT, known for delivering high doses of radiation with sub-millimeter precision, significantly reduces treatment time and spares adjacent healthy tissues. MRI-guided radiation therapy, meanwhile, allows for real-time visualization of tumors during treatment, enabling adaptive treatments that account for anatomical changes and tumor motion, thus enhancing therapeutic efficacy.

Dr. Kishan has significantly contributed to the design and execution of several landmark trials that push the boundaries of radiation oncology. Among these, the MIRAGE study utilized MRI-guided SBRT for prostate cancer, demonstrating superior toxicity profiles and cancer control rates compared to conventional approaches. The LUNAR trial, another key endeavor, explores precise dose escalation in bladder cancer treatments while mitigating treatment-related side effects. Additionally, the recently initiated HEATWAVE trial investigates novel thermoradiotherapy combinations to sensitize tumors while preserving healthy tissue integrity, underpinning the future direction of multimodal cancer therapies.

His scholarly output is equally impressive, with over 310 peer-reviewed publications in top-tier medical journals such as JAMA, The Lancet Oncology, and the Journal of Clinical Oncology. This extensive body of work provides the scientific community with critical evidence on enhancing the therapeutic window of radiation therapy—maximizing tumor eradication while minimizing adverse effects. Dr. Kishan’s research emphasizes the dual goals of improving cancer control rates and patient quality of life, reflecting a patient-centered approach in oncologic care.

Central to Dr. Kishan’s research philosophy is his focus on translational science, bridging the gap between laboratory discoveries and clinical application. His investigations into molecular imaging and nanotechnology facilitate the identification of radiobiological markers and enable theranostic or targeted therapeutic approaches. By harnessing molecular imaging modalities, his work aims to better characterize tumor heterogeneity, understand resistance mechanisms, and tailor radiation doses to the biological behavior of individual cancers, thus advancing personalized medicine in oncology.

Dr. Kishan’s dedication extends beyond research; he is also deeply committed to compassionate clinical care and mentorship. He has been recognized with the Leonard Tow Humanism in Medicine Award in 2021, underscoring his empathetic approach toward patients and his role in nurturing the next generation of clinicians and researchers. His mentorship fosters an environment where scientific inquiry and clinical excellence coexist, ensuring sustained innovation in cancer treatment paradigms.

The support Dr. Kishan has garnered from prestigious agencies, including the National Institutes of Health, the Department of Defense, and the Prostate Cancer Foundation, speaks to the transformative potential of his work. These grants facilitate high-impact research initiatives aimed at improving survival outcomes and reducing the morbidity associated with current cancer therapies. His ability to secure sustained funding reflects the confidence of the scientific and medical communities in the significance and rigor of his research portfolio.

In the context of prostate cancer, Dr. Kishan’s work has redefined treatment paradigms by demonstrating that advanced precision radiation techniques can rival, and potentially surpass, traditional approaches in both efficacy and safety. This work aligns with emerging trends in oncology focused on minimally invasive treatments that maintain high cure rates without compromising urinary, sexual, or bowel function. His research increasingly informs clinical guidelines, helping set new standards for care.

Bladder cancer research under Dr. Kishan’s leadership similarly benefits from innovations in radiation delivery and combination therapies. By employing hypofractionated radiation schedules coupled with systemic agents, his research aims to enhance tumor control while shortening overall treatment durations. Such advances have the potential to transform bladder cancer management, reducing healthcare costs and patient burden without compromising outcomes.

Dr. Michael Steinberg, professor and chair of radiation oncology at UCLA’s David Geffen School of Medicine and director of Clinical Affairs at the UCLA Health Jonsson Comprehensive Cancer Center, lauds Dr. Kishan’s scientific rigor and leadership. According to Dr. Steinberg, Dr. Kishan’s commitment exemplifies UCLA’s mission to drive innovation in cancer research and deliver state-of-the-art care, highlighting the institution’s role as a hub for cutting-edge oncology advancements.

In summary, the recognition of Dr. Amar Kishan with the 2025 Steven A. Leibel Memorial Award is a testament to his transformative contributions to radiation oncology. His pioneering work in precision radiation techniques, translational research, and compassionate patient care continues to advance the frontier of cancer treatment. The impact of his research promises to enhance therapeutic efficacy, reduce treatment-related morbidity, and improve the lives of countless patients facing prostate and bladder cancers worldwide.

Subject of Research: Radiation therapy advancements and translational research in prostate and bladder cancers
Article Title: Dr. Amar Kishan Honored with the 2025 Steven A. Leibel Memorial Award for Innovations in Radiation Oncology
News Publication Date: 2024
Web References:
– https://www.uclahealth.org/providers/amar-kishan
– https://www.uclahealth.org/cancer
References:
– JAMA, The Lancet Oncology, Journal of Clinical Oncology (select publications by Dr. Amar Kishan)
Image Credits: Information not provided
Keywords: Radiation therapy, Cancer, Prostate cancer, Medical treatments

Prostate cancer remains the second most prevalent malignancy among men globally, often presenting a formidable challenge when it recurs after initial treatment. Oligorecurrent prostate cancer, characterized by a small number of new metastatic lesions, demands precise and effective therapeutic interventions. SBRT, a form of high-precision radiation that targets tumors while sparing surrounding healthy tissue, has become the standard for managing these cases. However, many patients eventually experience relapse, primarily due to microscopic disease invisible on conventional imaging.

To address this, the UCLA-led LUNAR phase 2 trial investigated whether incorporating a PSMA-targeted radioligand, specifically the molecule 177Lu-PNT2002, prior to SBRT could better eradicate both visible and occult prostate cancer cells. Prostate-specific membrane antigen (PSMA) is a protein abundantly expressed on prostate cancer cells, making it an ideal target for radioligand therapies. Unlike traditional radiation, radioligand therapy delivers targeted radiation via radioactive isotopes linked to molecules that bind directly to cancer cells, minimizing collateral damage to healthy tissues.

The trial enrolled 92 men with oligorecurrent prostate cancer and randomly assigned them to two groups. The control arm received SBRT alone, while the experimental arm received two doses of 177Lu-PNT2002 before SBRT. Patients were monitored through prostate-specific antigen (PSA) blood tests and advanced PSMA PET imaging to evaluate disease progression. Remarkably, those treated with the combination therapy exhibited a median progression-free survival of 17.6 months, more than twice that of the SBRT-only group, which demonstrated 7.4 months.

This substantial improvement translated into a 63% reduction in the combined risk of cancer progression, initiation of hormone therapy, or death. Importantly, the addition of 177Lu-PNT2002 delayed the initiation of androgen deprivation therapy (ADT)—a cornerstone treatment for advanced prostate cancer known for its severe side effects such as fatigue, sexual dysfunction, and bone density loss. Men receiving the combination therapy enjoyed a median of 24.3 months before hormone therapy became necessary, compared to 14.1 months in the SBRT-alone cohort.

The success of this combined modality stems not only from its capacity to target PSMA-expressing cancer cells visible on PET scans but also from its potential to eradicate microscopic disease lingering beneath the detection threshold. By harnessing PSMA PET imaging to precisely guide SBRT targeting and coupling it with radioligand therapy, the researchers created a dual-attack strategy that addresses both macroscopic and microscopic cancer deposits.

Additionally, the LUNAR trial delved into biological markers that could predict patient responses to treatment. The researchers analyzed T cell receptor changes post-SBRT, immunological shifts associated with improved clinical outcomes. Furthermore, a gene expression signature encompassing 20 genes linked to immune function and DNA repair differentiated patients at higher risk of disease progression from those more likely to benefit from therapy, opening avenues toward personalized treatment approaches.

Despite the profound benefits observed, the trial underscored ongoing challenges, as 64% of men still experienced disease progression. This high relapse rate highlights the complexity of micrometastatic prostate cancer and suggests the need for further refinements in both therapeutic delivery and precision targeting.

Dr. Amar Kishan, the executive vice chair of radiation oncology and co-director of the cancer molecular imaging, nanotechnology, and theranostics program at UCLA, emphasized the significance of these findings: “Our research provides pivotal proof of principle that radioligand therapy can be effectively and safely integrated earlier in prostate cancer treatment, offering patients meaningful delays in disease progression and hormone therapy initiation without additional toxicity.”

Moreover, Dr. Jeremie Calais, the trial’s senior author and director of the Ahmanson Translational Theranostics Division, highlighted the synergy achieved through collaboration between radiation oncology and nuclear medicine. This interdisciplinary approach exemplifies the promise of theranostics—a field combining diagnostic imaging and targeted therapy—to revolutionize cancer care paradigms.

The safety profile of the combination therapy was also encouraging, with minimal adverse effects reported, reinforcing its potential for broader clinical application. Nevertheless, the investigators acknowledge the necessity for longer-term follow-up and exploration of strategies to enhance response rates, such as optimizing dosing schedules or combining with immunotherapies.

This study not only propels forward the clinical utility of PSMA-targeted radioligand agents beyond advanced metastatic settings but also redefines the therapeutic landscape for men with oligorecurrent disease. By extending progression-free survival and postponing hormone therapy, this approach promises to improve both survival and quality of life for countless patients worldwide.

Funded by Lantheus, the LUNAR trial represents a milestone in prostate cancer research, illuminating a new path for early intervention that leverages molecular targeting and state-of-the-art imaging to outmaneuver one of the most common and insidious cancers affecting men today.

Subject of Research: Prostate cancer treatment using PSMA-targeted radioligand therapy combined with stereotactic body radiotherapy (SBRT).

Article Title: New Radioligand Therapy Combined with Radiotherapy Doubles Progression-Free Survival in Recurrent Prostate Cancer

News Publication Date: 2025

Web References:

• UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
• 2025 ASTRO Annual Meeting Session: https://amportal.astro.org/sessions/ct-01-21645/177-lutetium-psma-neoadjuvant-to-ablative-radiotherapy-for-oligorecurrent-prostate-cancer-pri-109077
• Dr. Amar Kishan Profile: https://www.uclahealth.org/providers/amar-kishan
• Dr. Jeremie Calais Profile: https://www.uclahealth.org/cancer/members/jeremie-calais

Keywords: Prostate cancer, PSMA-targeted radioligand therapy, stereotactic body radiotherapy, oligorecurrent disease, progression-free survival, androgen deprivation therapy, theranostics, prostate-specific membrane antigen, 177Lu-PNT2002, molecular imaging, cancer treatment innovations.